MemberHealth Makes a Move

Three months in to Medicare Part D, the stand-alone drug insurance market is heavily concentrated. Not surprisingly, United has the biggest share. But one member of the top tier--MemberHealth--is an unlikely heavyweight.

Fifty-four different companies entered the stand-alone prescription drug insurance market under Medicare Part D Jan. 1. But, even before the program began, it was clear that not all 54 would be competing on an equal footing in the race for enrollment in 2006. A handful of companies dominated the initial enrollment in Part D, because they bid most aggressively to serve former Medicaid recipients who were randomly assigned to plans. (See "Medicare Market Share: Drug Plan Starts With Big Four," IN VIVO, October, 2005 Also see "Medicare Market Share: Drug Plan Starts With Big Four" - In Vivo, 1 October, 2005..)

Three months into the program, the market is even more concentrated. The top 10 plan sponsors represent about 90% of the enrollment in Part D, and the top five companies...

More from Market Access

GLP-1 Pricing ‘Paradigm Shift’ Possible, But Would It Meet Trump’s MFN Goals?

 
• By 

For the Trump Administration, the blockbuster GLP-1 drugs for obesity have become a poster child for the disparity between US and foreign prices.

Japan Price Cuts For Epkinly and Lunsumio Following CEA

 
• By 

Japan is cutting more drug reimbursement prices following cost effectiveness analysis and is applying the methodology to a new group of products including Wegovy and Leqembi.

Rocky Rollout Spells Trouble for Medicare Prescription Payment Plan

 

Enrollment in the new Medicare Prescription Payment Plan was lower than expected in the first year and well below CMS expectations, and invoicing data indicates members are slow to pay.

PBM Investigation, Enforcement Action ‘Critical Priorities’ At FTC, Chair Says

 
• By 

The new FTC chair addressed concerns that staffing cuts will undermine the commission’s commitment to pharmacy benefit manager oversight.

More from Pink Sheet

How Pharma Companies Can Mitigate The Impact Of US Tariffs On The Supply Chain

 
• By 

If US tariffs on pharmaceutical supply chain products come into force they could be disruptive for companies. Ewan Townsend, of the international law firm Arnold & Porter, explains how companies can mitigate issues through negotiating with suppliers and reallocating tariff responsibilities.

‘The Question Is, What’s Going To Happen Next?’ – The Future For Biosimilars In Europe

 
• By 

With European biosimilars developers buoyed by recent regulatory moves, Medicines for Europe’s Isabell Remus and Julie Maréchal-Jamil discuss the next steps forward for the industry.